Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 110 East 59th Street NEW YORK NY 10022 |
Tel: | N/A |
Website: | https://www.royaltypharma.com |
IR: | See website |
Key People | ||
Pablo Legorreta Chairman of the Board, Chief Executive Officer | Christopher D. Hite Vice Chairman, Executive Vice President | Terrance Coyne Chief Financial Officer, Executive Vice President |
George Lloyd Executive Vice President - Investments and Chief Legal Officer | Marshall Urist Executive Vice President - Research and Investments | Eric Schneider Senior Vice President, Chief Technology Officer |
Business Overview |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Royalty Pharma plc revenues increased 5% to $2.35B. Net income increased from $42.8M to $1.13B. Revenues reflect Other royalty income increase from $74.6M to $156M, Income from financial royalty assets increase of 3% to $2.2B. Net income benefited from Financial royalty asset impairment decrease from $615.8M (expense) to $0K. |
Employees: | 89 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $21,618M as of Dec 31, 2023 |
Annual revenue (TTM): | $2,355M as of Dec 31, 2023 |
EBITDA (TTM): | $1,492M as of Dec 31, 2023 |
Net annual income (TTM): | $1,135M as of Dec 31, 2023 |
Free cash flow (TTM): | $513.95M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $4,902M as of Dec 31, 2023 |
Shares outstanding: | 597,484,791 as of Feb 9, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |